Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACURA PHARMACEUTICALS, INCACUR · Entity 69367 | 10% owner | June 09, 2021 | June 28, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACURA PHARMACEUTICALS, INC
Report date June 09, 2021 · Filed June 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Abuse Deterrent Pharma, LLC | 42,984,375 |
Reported balance
After 2021-06-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-06-09 · Conversion · Acquired 42,984,375 · Balance 42,984,375 F1: The Reporting Person is the manager and a member of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of the securities, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.16 | IndirectBy Abuse Deterrent Parma, LLC | 0 |
Reported balance
After 2021-06-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-06-09 · Conversion · Disposed Not disclosed · Balance 0 F2: On the conversion date, $6,000,000 of principal and $877,500 of interest under the note was converted into the Issuer's common stock. For each $0.16 converted, AD Pharma received one share of common stock. F3: This note is convertible, at the election of AD Pharma, at any time prior to repayment of the note and matures on July 1, 2023. F1: The Reporting Person is the manager and a member of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of the securities, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 8,912,655 |
Reported balance
Holding disclosure · report date 2021-06-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 8,912,655 |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.53 · Expires 2022-07-23 | Direct | 1,782,531 |
Reported balance
Holding disclosure · report date 2021-06-09 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,782,531 |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2024-06-28 | IndirectBy Abuse Deterrent Parma, LLC | 10,000,000 |
Reported balance
Holding disclosure · report date 2021-06-09 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 10,000,000 F1: The Reporting Person is the manager and a member of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of the securities, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is the manager and a member of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of the securities, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2: On the conversion date, $6,000,000 of principal and $877,500 of interest under the note was converted into the Issuer's common stock. For each $0.16 converted, AD Pharma received one share of common stock.
F3: This note is convertible, at the election of AD Pharma, at any time prior to repayment of the note and matures on July 1, 2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Stock Yards Bancorp, Inc.
Report date April 28, 2026 · Filed April 29, 2026
Section 16 reporting ended · disclosed 2026-04-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectTrust Director Deferred Comp Plan | 9,062 |
Reported balance
After 2026-04-28 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-04-28 · Grant · Acquired 55 · Balance 9,062 F1: Includes shares acquired through automatic dividend reinvestment. |
| Common StockSEC Table I · non-derivative | Direct | 82,940 |
Reported balance
Holding disclosure · report date 2026-04-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 82,940 F2: Restricted Stock Unit cancelled |
| Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $38.85 · Expires 2028-08-28 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2026-04-28 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares acquired through automatic dividend reinvestment.
F2: Restricted Stock Unit cancelled
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 25, 2022 Filed Oct 27, 2022 19:44 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 59 | $73.25 | $4,321.75 |
DisclosureSEC source: 0001437749-22-024935 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 4,609 F1 · balance_after: Includes shares acquired through automatic dividend reinvestment. Read SEC document |
| September 28, 2022 Filed Sep 29, 2022 20:11 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 33 | $69.64 | $2,298.12 |
DisclosureSEC source: 0001437749-22-023244 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 4,531 Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 20:00 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 45 | $69.60 | $3,132.00 |
DisclosureSEC source: 0001437749-22-021448 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 4,498 Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 12:51 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 78 | $65.85 | $5,136.30 |
DisclosureSEC source: 0001437749-22-018080 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 4,453 F1 · balance_after: Includes shares acquired through automatic dividend reinvestment. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 18:53 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 26 | $58.57 | $1,522.82 |
DisclosureSEC source: 0001437749-22-015854 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 4,355 Read SEC document |
| May 20, 2022 Filed May 24, 2022 14:28 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 59 | $53.06 | $3,130.54 |
DisclosureSEC source: 0001437749-22-013357 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 4,329 Read SEC document |
| April 29, 2022 Filed May 3, 2022 15:22 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 105 | $52.86 | $5,550.30 |
DisclosureSEC source: 0001437749-22-010606 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 4,270 F1 · balance_after: Includes shares acquired through automatic dividend reinvestment. Read SEC document |
| March 18, 2022 Filed Mar 21, 2022 19:05 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 42 | $54.66 | $2,295.72 |
DisclosureSEC source: 0001437749-22-006815 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 4,144 Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 20:08 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 94.019 | $54.51 | $5,124.98 |
DisclosureSEC source: 0001437749-22-003805 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 4,102 Read SEC document |
| January 27, 2022 Filed Jan 28, 2022 19:21 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 86.615 | $59.17 | $5,125.01 |
DisclosureSEC source: 0001437749-22-001851 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 4,008 Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 20:13 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 541 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-000398 · rdgdoc.xml · nonDerivative · entry 1 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,437 F1 · price: Restricted stock unit grant with one year vesting. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 21:21 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 38.225 | $60.17 | $2,300.00 |
DisclosureSEC source: 0001437749-21-029106 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 3,904 Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 20:54 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 60.07 | $65.34 | $3,924.97 |
DisclosureSEC source: 0001437749-21-027067 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 3,866 Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 13:48 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 68.218 | $63.40 | $4,325.02 |
DisclosureSEC source: 0001437749-21-024201 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 3,806 F1 · balance_after: Includes shares acquired through automatic dividend reinvestment. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 18:29 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 38.786 | $59.30 | $2,300.01 |
DisclosureSEC source: 0001437749-21-023075 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 3,721 Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:05 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 61 | $51.64 | $3,150.04 |
DisclosureSEC source: 0001437749-21-020855 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 3,682 Read SEC document |
| July 23, 2021 Filed Jul 26, 2021 20:45 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 109.814 | $46.67 | $5,125.02 |
DisclosureSEC source: 0001437749-21-017570 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 3,622 F1 · balance_after: Includes shares acquired through automatic dividend reinvestment. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:06 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 28.98 | $51.76 | $1,500.00 |
DisclosureSEC source: 0001437749-21-015229 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 3,493.404 Read SEC document |
| June 09, 2021 Filed Jun 28, 2021 14:53 UTC | ACURA PHARMACEUTICALS, INC ACUR · Entity 69367 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $0.00 Strike: $0.16 | $6,877,500.00 |
DisclosureSEC source: 0001567619-21-012641 · doc1.xml · derivative · entry 5 Schutte John · CIK 0001713580 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Abuse Deterrent Parma, LLC Disclosed balance after: 0 Underlying: Common Stock · 42,984,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · reported_value: On the conversion date, $6,000,000 of principal and $877,500 of interest under the note was converted into the Issuer's common stock. For each $0.16 converted, AD Pharma received one share of common stock. F3 · derivative.expiration_date: This note is convertible, at the election of AD Pharma, at any time prior to repayment of the note and matures on July 1, 2023. F1 · ownership.nature: The Reporting Person is the manager and a member of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of the securities, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 09, 2021 Filed Jun 28, 2021 14:53 UTC | ACURA PHARMACEUTICALS, INC ACUR · Entity 69367 | ConversionCommon Stock | 42,984,375 | $0.16 | $6,877,500.00 |
DisclosureSEC source: 0001567619-21-012641 · doc1.xml · nonDerivative · entry 2 Schutte John · CIK 0001713580 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Abuse Deterrent Pharma, LLC Disclosed balance after: 42,984,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The Reporting Person is the manager and a member of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of the securities, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 20, 2021 Filed May 21, 2021 18:47 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 60.809 | $51.39 | $3,124.97 |
DisclosureSEC source: 0001437749-21-013030 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 3,464.424 Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 18:15 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 84.144 | $51.40 | $4,325.00 |
DisclosureSEC source: 0001437749-21-009886 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 3,403.615 F1 · balance_after: Includes shares acquired through automatic dividend reinvestment. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 14:41 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 28.969 | $51.78 | $1,500.01 |
DisclosureSEC source: 0001437749-21-006579 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 3,302.273 Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 15:25 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 116.841 | $50.71 | $5,925.01 |
DisclosureSEC source: 0001437749-21-004181 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 3,273.304 Read SEC document |
| January 27, 2021 Filed Jan 28, 2021 19:19 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 38.235 | $42.50 | $1,624.99 |
DisclosureSEC source: 0001437749-21-001477 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 3,156.463 Read SEC document |
| January 20, 2021 Filed Jan 21, 2021 18:00 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 121.561 | $42.16 | $5,125.01 |
DisclosureSEC source: 0001437749-21-000981 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 3,118.228 Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:31 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 862 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-000268 · rdgdoc.xml · nonDerivative · entry 1 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,896 F1 · price: Restricted stock unit grant with one year vesting. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 19:13 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 55.156 | $41.70 | $2,300.01 |
DisclosureSEC source: 0001437749-20-025463 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 2,976.812 Read SEC document |
| November 18, 2020 Filed Nov 19, 2020 21:26 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 94.67 | $41.46 | $3,925.02 |
DisclosureSEC source: 0001437749-20-024244 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 2,921.656 Read SEC document |
| October 22, 2020 Filed Oct 23, 2020 17:04 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 112.718 | $38.37 | $4,324.99 |
DisclosureSEC source: 0001437749-20-021548 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 2,826.987 F1 · balance_after: Includes shares acquired through automatic dividend reinvestment. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 18:33 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 57.214 | $40.20 | $2,300.00 |
DisclosureSEC source: 0001437749-20-019809 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 2,692.986 Read SEC document |
| August 19, 2020 Filed Aug 20, 2020 16:26 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 73.168 | $42.71 | $3,125.01 |
DisclosureSEC source: 0001437749-20-018441 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 2,635.772 Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 12:54 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 126.2 | $40.61 | $5,124.98 |
DisclosureSEC source: 0001437749-20-015739 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 2,562.604 F1 · balance_after: Includes shares acquired through automatic dividend reinvestment. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 16:41 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 41.22 | $36.39 | $1,500.00 |
DisclosureSEC source: 0001437749-20-013531 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 2,419.602 Read SEC document |
| May 20, 2020 Filed May 21, 2020 15:48 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 101.002 | $30.94 | $3,125.00 |
DisclosureSEC source: 0001437749-20-011512 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 2,378.382 Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 14:37 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 145.134 | $29.80 | $4,324.99 |
DisclosureSEC source: 0001437749-20-008528 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 2,277.38 F1 · balance_after: Includes shares acquired through automatic dividend reinvestment. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 14:32 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 86.564 | $26.57 | $2,300.01 |
DisclosureSEC source: 0001437749-20-005639 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 2,112.47 Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 17:45 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 158.847 | $37.30 | $5,924.99 |
DisclosureSEC source: 0001437749-20-003557 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 2,025.907 Read SEC document |
| January 23, 2020 Filed Jan 24, 2020 21:55 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 87.675 | $39.92 | $3,499.99 |
DisclosureSEC source: 0001437749-20-001168 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 1,867.059 Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:38 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-000166 · rdgdoc.xml · nonDerivative · entry 1 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,034 F1 · price: Restricted stock unit grant with one year vesting. Read SEC document |
| December 26, 2019 Filed Dec 27, 2019 21:15 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 55.758 | $41.25 | $2,300.02 |
DisclosureSEC source: 0001437749-19-024957 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 1,768.124 Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 19:44 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 126.076 | $40.65 | $5,124.99 |
DisclosureSEC source: 0001437749-19-023438 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 1,712.366 Read SEC document |
| October 17, 2019 Filed Oct 18, 2019 15:45 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 117.655 | $36.76 | $4,325.00 |
DisclosureSEC source: 0001437749-19-020251 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 1,586.29 F1 · balance_after: Includes shares acquired through automatic dividend reinvestment. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 16:30 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 61.17 | $37.60 | $2,299.99 |
DisclosureSEC source: 0001437749-19-018877 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 1,458.487 Read SEC document |
| August 21, 2019 Filed Aug 22, 2019 18:56 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 86.493 | $36.13 | $3,124.99 |
DisclosureSEC source: 0001437749-19-017290 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 1,397.317 Read SEC document |
| July 22, 2019 Filed Jul 23, 2019 18:41 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 147.652 | $34.71 | $5,125.00 |
DisclosureSEC source: 0001437749-19-014442 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 1,310.824 F1 · balance_after: Includes shares acquired through automatic dividend reinvestment. Read SEC document |
| June 28, 2019 Filed Jul 11, 2019 20:07 UTC | ACURA PHARMACEUTICALS, INC ACUR · Entity 69367 | OtherConvertible Promissory Note · Derivative | Not disclosed | $6,000,000.00 Strike: $0.16 | $6,000,000.00 |
DisclosureSEC source: 0001567619-19-014669 · doc1.xml · derivative · entry 6 Schutte John · CIK 0001713580 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Abuse Deterrent Parma, LLC Disclosed balance after: 375,000,000 Underlying: Common Stock · 375,000,000 shares Expires not disclosed F7 · kind: Reflects the assignment and transfer of the Note by the Reporting Person to AD Pharma. F5 · reported_value: The Note bears interest at the rate of 7.5% per annum. At the election of AD Pharma, all principal and deemed interest under the Note may be converted into the Issuer's common stock. For each $0.16 converted, AD Pharma will receive one share of common stock. F6 · derivative.expiration_date: The Note is convertible, at the election of AD Pharma, at any time prior to repayment of the Note and matures on July 1, 2023. F9 · derivative.underlying_shares: Excludes any interest accruing on the Note, which is convertible at the election of AD Pharma. F9 · balance_after: Excludes any interest accruing on the Note, which is convertible at the election of AD Pharma. F8 · ownership.nature: The Reporting Person is the manager and indirect 61.1% owner of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of the Note, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the Note for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 28, 2019 Filed Jul 11, 2019 20:07 UTC | ACURA PHARMACEUTICALS, INC ACUR · Entity 69367 | OtherConvertible Promissory Note · Derivative | Not disclosed | $6,000,000.00 Strike: $0.16 | $6,000,000.00 |
DisclosureSEC source: 0001567619-19-014669 · doc1.xml · derivative · entry 5 Schutte John · CIK 0001713580 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000,000 Underlying: Common Stock · 375,000,000 shares Expires not disclosed F4 · kind: The Note amended, consolidated and restated the existing promissory notes issued to the Reporting Person into a single note in the amount of $6 million and added the conversion right. F5 · reported_value: The Note bears interest at the rate of 7.5% per annum. At the election of AD Pharma, all principal and deemed interest under the Note may be converted into the Issuer's common stock. For each $0.16 converted, AD Pharma will receive one share of common stock. F6 · derivative.expiration_date: The Note is convertible, at the election of AD Pharma, at any time prior to repayment of the Note and matures on July 1, 2023. F9 · derivative.underlying_shares: Excludes any interest accruing on the Note, which is convertible at the election of AD Pharma. F9 · balance_after: Excludes any interest accruing on the Note, which is convertible at the election of AD Pharma. Read SEC document |
| June 28, 2019 Filed Jul 11, 2019 20:07 UTC | ACURA PHARMACEUTICALS, INC ACUR · Entity 69367 | OtherWarrant to Purchase Common Stock · Derivative | 10,000,000 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001567619-19-014669 · doc1.xml · derivative · entry 4 Schutte John · CIK 0001713580 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Abuse Deterrent Parma, LLC Disclosed balance after: 10,000,000 Underlying: Common Stock · 10,000,000 shares Expires 2024-06-28 F2 · kind: Reflects the assignment and transfer of the warrant by the Reporting Person to Abuse Deterrent Pharma, LLC ("AD Pharma"). F1 · price: This warrant was issued to the Reporting Person in connection with the amended, consolidated and restated convertible secured promissory note in the amount of $6 million (the "Note"). F3 · ownership.nature: The Reporting Person is the manager and indirect 61.1% owner of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of this warrant, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the warrant for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| June 28, 2019 Filed Jul 11, 2019 20:07 UTC | ACURA PHARMACEUTICALS, INC ACUR · Entity 69367 | OtherWarrant to Purchase Common Stock · Derivative | 10,000,000 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001567619-19-014669 · doc1.xml · derivative · entry 3 Schutte John · CIK 0001713580 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000,000 Underlying: Common Stock · 10,000,000 shares Expires 2024-06-28 F1 · kind: This warrant was issued to the Reporting Person in connection with the amended, consolidated and restated convertible secured promissory note in the amount of $6 million (the "Note"). F1 · price: This warrant was issued to the Reporting Person in connection with the amended, consolidated and restated convertible secured promissory note in the amount of $6 million (the "Note"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.